ARTICLE: The Benefit of Artificial Intelligence-Based Diagnosis in Gastroenterology and Hepatology Is Highly Variable: A Diagnostic Need and Burden Analysis
AUTHORS: Viveka Chinnasamy, Vorada Sakulsaengprapha, Simon C. Mathews
JOURNAL: Gastroenterology. 2023 Jun 2;S0016-5085(23)00818-1. doi: 10.1053/j.gastro.2023.05.045. Online ahead of print.
Artificial intelligence (AI) for diagnostic purposes represents a potential technology breakthrough in medicine. Its diagnostic application within gastroenterology and hepatology conditions has grown quickly and robustly, with its first United States Food and Drug Administration authorization for use in 2021. As research funding and commercial development continue at a fast pace, the question of where AI-based diagnosis can have the biggest impact has not been sufficiently addressed. Although improvement in the diagnosis of any condition has benefits, there are also real costs associated with implementing AI-based solutions and opportunity costs associated with prioritizing funding and development decisions.
Our aim was to identify the spectrum of diagnostic gaps within gastroenterology and hepatology conditions and analyze their relationship with major drivers of burden, including prevalence, mortality, and cost to determine where AI-based diagnostics will have the greatest benefit. We also wished to highlight existing examples of AI-guided diagnosis to illustrate the relative state of progress across these conditions.
For the full article, click here.
